Medline Inc. faced significant FDA violations related to manufacturing quality, including failure to investigate contamination and cleaning issues, leading to a stock drop of over 7% initially. The stock further fell by more than 12% following disappointing Q2 results and reduced full-year adjusted EBITDA guidance. Investors who suffered losses may have legal rights under federal securities laws, with a law firm currently investigating potential violations. This situation highlights risks in Medline's compliance and financial outlook, affecting investor confidence.
BMO Capital initiated coverage on Tenet Healthcare with a 'Market Perform' rating, indicating the stock is expected to perform in line with the broader market. The company is forecasted to report a 24.05% increase in Earnings Per Share (EPS) to $4.59...
Jaguar Health (JAGX) surged over 1,150% after the FDA granted fee waivers for its drugs Mytesi and Canalevia-CA1, signaling regulatory support. Greenland Mines (GRML) rose nearly 50% amid growing investor interest linked to U.S.-Greenland security de...
The market experienced a downturn with significant losses among key stocks. New Fortress Energy dropped 24.7% amid ongoing volatility in energy sectors, while Xanadu Quantum Technologies fell 21.7% reflecting sensitivity in quantum stocks to commerci...
Jefferies maintains a Hold rating on Capri Holdings due to uncertainty over a potential takeover. Despite a flat global luxury market, Capri's management expects growth in the second half of 2026, driven by new product launches, increased marketing, ...
The Vanguard Information Technology ETF (VGT) excludes major tech-adjacent companies like Alphabet (Google), Meta, and Amazon due to a 2018 sector reclassification that moved these firms out of the Information Technology sector. Instead, VGT focuses ...
